Economic impact and chronic obstructive pulmonary disease outcomes of a comprehensive inhaler to nebulization therapy protocol implementation in a large multi-state healthcare system

References

• NORC at the University of Chicago. Final report: trends in hospital inpatient drug costs: issues and challenges [Internet]. 2016 [cited 2018 Dec 7]. Available from: https://www.aha.org/system/files/2018-01/aha-fah-rx-report.pdf
   Google Scholar
• GoodRx: here’s why asthma inhalers are so expensive [Internet]. [cited 2019 Jan 31]. Available from: https://www.goodrx.com/blog/heres-why-asthma-inhalers-are-so-expensive/
   Google Scholar
• Ford ES. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001–2012 and Nationwide Emergency Department Sample 2006–2011. Chest. 2015;147:989–998.
   PubMed Web of Science ®Google Scholar
• Jinjuvadia C, Jinjuvadia R, Mandapakala C, et al. Trends in outcomes, financial burden, and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD) in the United States from 2002 to 2010. COPD. 2017;14:72–79. Feb
   PubMedGoogle Scholar
• Sakaan S, Ulrich D, Luo J, et al. Inhaler use in hospitalized patients with chronic obstructive pulmonary disease or asthma: assessment of wasted doses. Hosp Pharm. 2015;50:386–390.
   PubMedGoogle Scholar
• Ware MD, Nguyen T. Strategy to eliminate waste with metered dose inhalers (MDIs) in adult chronic obstructive pulmonary disease (COPD) patients in an acute care community hospital. Poster presentation at the American Society of Health-System Pharmacists 2018 Midyear Clinical Meeting; Ahaheim, CA.
   Google Scholar
• Larson T, Gudavalli R, Prater D, et al. Critical analysis of common canister programs: a review of cross-functional considerations and health system economics. Curr Med Res Opin. 2015;31:853–860.
   PubMed Web of Science ®Google Scholar
• Glick J, Gonzalez E. Therapeutic interchange protocol of orally inhaled medications to administration via nebulizer: impact on the incidence and cost of wasted doses. Poster presentation at the American Society of Health-System Pharmacists 2018 Midyear Clinical Meeting; Ahaheim, CA.
   Google Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335–371.
   PubMed Web of Science ®Google Scholar
• Press VG, Arora VM, Shah LM, et al. Misuse of respiratory inhalers in hospitalized patients with asthma or COPD. J Gen Intern Med. 2011;26:635–642.
   PubMed Web of Science ®Google Scholar
• Tratto KD, Gomez C, Ryan CJ, et al. Nurses knowledge of inhaler technique in the inpatient hospital setting. Clin Nurse Spec. 2014;28:156–160.
   PubMed Web of Science ®Google Scholar
• Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of low peak inspiratory flow rates at discharge in patients hospitalized for COPD exacerbation. J COPD F. 2017;4:217–224.
   PubMedGoogle Scholar
• Loh CH, Peters SP, Lovings TM, et al. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Annals ATS. 2017;14:1305–1311.
   Web of Science ®Google Scholar
• Ghosh S, Ohar JA, Drummond MB. Peak inspiratory flow rate in chronic obstructive pulmonary disease: implications for dry power inhalers. J Aersol Med Pulm Drug Deliv. 2017;30:381–387.
   PubMed Web of Science ®Google Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14:1103–1107.
   PubMed Web of Science ®Google Scholar
• Wild D. Bright ideas for boosting savings – and patient care [Internet]. Pharm Pract News; February 2014. [cited 2019 Jan 31]. Available from: https://www.pharmacypracticenews.com/Operations-and-Management/Article/02-14/Bright-Ideas-for-Boosting-Savings—and-Patient-Care/25850
   Google Scholar
• Yoon J, Hebert N, Freeland H. Efficacy of a protocol to eliminate use of metered-dose inhalers in favor of nebulization therapy for inpatient respiratory care. Chest. 2014;146:551A. (4_MeetingAbstracts): doi:10.1378/chest.1973537
   Google Scholar
• Strozyk W, Norris C, Ryman M. Quality, productivity and economic results of a metered dose inhaler to nebulizer interchange in a large, regional referral medical center. Poster presentation at the American Society of Health-System Pharmacists 2014 Midyear Clinical Meeting; Ahaheim, CA.
   Google Scholar
• McDonough K, Gonzalez S, Sunnongmuang S, et al. Therapeutic substitution of long acting beta agonist/corticosteroid metered dose inhalers arformoterol and budesonide via nebulization at a 210-bed urban hospital. Poster presentation at the American Society of Health-System Pharmacists 2012 Midyear Clinical Meeting; Las Vegas, NV.
   Google Scholar
• Glick J, Gonzalez E. Therapeutic interchange protocol of orally inhaled medications to administration via nebulizer: financial impact. Poster presentation at the American Society of Health-System Pharmacists 2018 Midyear Clinical Meeting; Ahaheim, CA.
   Google Scholar
• Glick J. Gonzalez E. Therapeutic interchange protocol or orally inhaled medications to administration via nebulizer: impact on the incidence of therapeutic duplications. Poster presentation at the American Society of Health-System Pharmacists 2018 Midyear Clinical Meeting; Ahaheim, CA.
   Google Scholar
• Glick J, Gonzalez E. Therapeutic interchange protocol or orally inhaled medications to administration via nebulizer: effect on workload of respiratory therapists and registered nurses. Poster presentation at the American Society of Health-System Pharmacists 2018 Midyear Clinical Meeting; Ahaheim, CA.
   Google Scholar
• Pitts C. Knoblock A. Evaluating a formulary substitution of inhaled fluticasone to nebulized budesonide. Poster presentation at the American Society of Health-System Pharmacists 2018 Midyear Clinical Meeting; Ahaheim, CA.
   Google Scholar
• Loborec SM, Johnson SE, Keating EA. Financial effect of converting ipratropium–albuterol therapy from inhalers to nebulizer treatments at an academic health system. Am J Health Syst Pharm. 2016;73:121–125.
   PubMed Web of Science ®Google Scholar
• Streepy KS, Dawson AM, Grigonis AM, et al. Conversion from metered dose inhalers to a vibrating mesh nebulizer in long term acute care hospitals: cost effectiveness and respiratory staff perception. Poster presentation at the American Society of Health-System Pharmacists 2013; Orlando, FL.
   Google Scholar
• Blake G, Yaklic J, Cobb J. Transition from ipratropium/albuterol inhaler to nebulizer on quality and cost savings in ventilated patients. Poster presentation at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting; Orlando, FL.
   Google Scholar
• McDaniel C, Glynn B, Gudowski S, et al. Conversion of pressurized metered-dose inhaler to vibrating mesh nebulizer administered medications. Poster session presented at: Society of Critical Care Medicine 42nd Critical Care Congress, 2013 Jan 19–23; San Juan, Puerto Rico. Poster 404.
   Google Scholar
• Emberger JS, Brown JM, Killian L. Cost reduction using Aeroneb Solo in a medical ICU ventilator population. Poster presented at: American Association of Respiratory Care Congress; 2011 Nov 7; Tampa, FL.
   Google Scholar
• Dubosky MN, Chen YF, Henriksen ME, et al. Vibrating mesh nebulizer compared with metered-dose inhaler in mechanically ventilated subjects. Respir Care. 2017;62:391–395.
   PubMed Web of Science ®Google Scholar
• Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS Pharm Sci Tech. 2014;15:434–455.
   PubMed Web of Science ®Google Scholar
• Marcoux RM, Vogenberg FR. Hazardous waste compliance in health care settings. PT. 2015;40:115–118.
   PubMedGoogle Scholar
• From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Internet]. 2019. [cited 2019 Jan 31]. Available from: http://goldcopd.org.
   Google Scholar
• Quintana JM, Unzurrunzaga A, Garcia-Gutierrez S, et al. Predictors of hospital length of stay in patients with exacerbations of COPD: a cohort study. J Gen Intern Med. 2015;30:824–831.
   PubMed Web of Science ®Google Scholar
• Shanley LA, Lin H, Flores G. Factors associated with length of stay for pediatric asthma hospitalizations. J Asthma. 2015;52:471–477.
   PubMed Web of Science ®Google Scholar
• Sha T, Churpek MM, Perraillon MC, et al. Understanding why patients with COPD get readmitted. A large national study to delineate the Medicare population for the readmission penalty expansion. Chest. 2015;147:1219–1226.
   PubMed Web of Science ®Google Scholar
• Rinne ST, Castaneda J, Lindenauer PK, et al. Chronic obstructive pulmonary disease readmissions and other measures of hospital quality. Am J Respir Crit Care Med. 2017;196:47–55.
   PubMed Web of Science ®Google Scholar
• Ohar JA. Risks may not be reasons for COPD readmissions. Ann Am Thorac Soc. 2015;12:1259–1260.
   PubMed Web of Science ®Google Scholar
• Alismail A, Song CA, Terry MH, et al. Diverse inhaler devices: a big challenge for health-care professionals. Respir Care. 2016;61:593–599.
   PubMed Web of Science ®Google Scholar
• Plaza V, Giner J, Rodrigo GJ, et al. Errors in the use of inhalers by health care professionals: a systematic review. J Allergy Clin Immunol Pract. 2018;6:987–995.
   PubMed Web of Science ®Google Scholar
• Braman SS, Carlin BW, Hanania NA, et al. Results of a pulmonologist survey regarding knowledge and practices with inhalation devices for COPD. Respir Care. 2018;63:840–848.
   PubMed Web of Science ®Google Scholar
• Alshabanat A, Otterstatter MC, Sin DD, et al. Impact of a COPD comprehensive case management program on hospital length of stay and readmission rates. COPD. 2017;12:961–971.
   Google Scholar
• Silver PC, Kollef MH, Clinkscale D, et al. A respiratory therapist disease management program for subjects hospitalized with COPD. Respir Care. 2017;62:1–9.
   PubMed Web of Science ®Google Scholar
• Sanders MJ. Guiding inspiratory flow: development of the In-Check dial G16, a tool for improving inhaler technique. Pulm Med. 2017;2017:1.
   Web of Science ®Google Scholar
• Kamin W, Erdnuss F, Kramer I. Inhalation solutions – which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers – update 2013. J Cyst Fibros. 2014;13:243–250.
   PubMed Web of Science ®Google Scholar
• Burchett DK, Darko W, Zahra J, et al. Mixing and compatibility guide for commonly used aerosolized medications. Am J Health System Pharm. 2010;67:227–230.
   PubMed Web of Science ®Google Scholar
• Bonasia P, Cook C, Cheng Y, et al. Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs. Curr Med Res Opin. 2007;23:2477–2483.
   PubMed Web of Science ®Google Scholar
• Bonasia PJ, McVicar WK, Bill W, et al. Chemical and physical compatibility of levalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium. Respir Care. 2008;53:1716–1722.
   PubMed Web of Science ®Google Scholar
• Akapo S, Gupta J, Martinez E, et al. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions. Ann Pharmacother. 2008;42:1416–1424.
   PubMed Web of Science ®Google Scholar
• Steuber T, Shiltz D. Single-center retrospective evaluation of inhaled corticosteroid use for chronic obstructive pulmonary disease exacerbation patients receiving systemic corticosteroids. Hosp Pharm. 2016;51:841–846.
   PubMedGoogle Scholar
• Pearce JA, Shiltz DL, Ding Q. Effectiveness and safety comparison for systemic corticosteroid therapy with and without inhaled corticosteroids for COPD exacerbation management. Ann Pharmacother. 2018;52:1070–1077.
   PubMed Web of Science ®Google Scholar